Therapy Onboarding Optimization: Why the Analytics of Patient Drop-Off Requires a Closer Look

The following is a guest article by Yishai Knobel, CEO at RxWare
From April 2020 to August 2021, the healthcare solutions company Indegene looked at approximately 7.9 million emails sent by prescription drug companies across 15 different email campaigns. The results, reported in April 2022 by Fierce Pharma, highlighted the need for brands to more carefully manage how they engage with healthcare providers in a post-COVID world, where in-person meetings play second fiddle to the convenience of digital communication.
Of course, this finding should come as no surprise to anyone who has given their email address or phone number over to a digital marketing campaign. No one has ever complained about receiving too few marketing emails or text messages. It is easy to lose interest in a new product or get lost in a maze of hyperlinks. Regrettably, at the cost of our own health, this phenomenon extends to prescription drug regimens as well.
The growing percentage of specialty drug users engaging with therapy onboarding through their smartphone presents as a convenient solution for remote digital engagement, but can quickly spiral into a challenge. According to IQVIA data, the prescription abandonment rate had reached 17 percent overall by 2021, and 60 percent for claims with a monthly out-of-pocket cost of $125 or more ― a cost often associated with specialty drugs. This squandered revenue has led manufacturers to increase their focus on patient onboarding, the main point of drop-of...

Source: EMR and HIPAA - May 11, 2023 Category: Information Technology Authors: Guest Author Tags: Analytics/Big Data Communication and Patient Experience Health IT Company Healthcare IT Digital Communication Fierce Pharma Indegene IQVIA Patient Drop-Off Patient Onboarding prescription drugs RxWare Specialty Drugs Therapy Onbo Source Type: blogs